Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)
PHASE3Not yet recruitingINTERVENTIONAL
Enrollment
122
Participants
Timeline
Start Date
September 1, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
May 31, 2027
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG
QL2107
IV infusion.
DRUG
Keytruda®
IV infusion.
All Listed Sponsors
lead
Qilu Pharmaceutical Co., Ltd.
INDUSTRY
NCT07162883 - Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter